[CAS NO. 102040-03-9] Tubeimoside I

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [102040-03-9]

Catelog

SLK-S3814

Brand

Selleck

CAS

102040-03-9

DESCRIPTION [102040-03-9]

Overview

MDL	MFCD28396382
Molecular Weight	1319.43
Molecular Formula	C63H98O29
SMILES	O=C1[C@]23[C@](C=4[C@@](C)(CC2)[C@@]5(C)[C@@H](CC4)[C@]6(C)[C@@](CC5)([C@@](CO)(C)[C@]([C@@H](O)C6)(O[C@]7([C@](O[C@H]8[C@H](O)[C@@H](O)[C@H](CO8)OC(=O)C[C@](C)(O)CC(=O)O[C@@]9([C@@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)CO%10)[C@@H](O)[C@H](O[C@]%11([C@](O1)(OC[C@H](O)[C@@H]%11O)[H])[H])O[C@H]9C)[H])([C@@H](O)[C@H](O)[C@@H](CO)O7)[H])[H])[H])[H])(CC(C)(C)CC3)[H]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	0.7579 mL	3.7895 mL	7.5790 mL
5 mM	0.1516 mL	0.7579 mL	1.5158 mL
10 mM	0.0758 mL	0.3790 mL	0.7579 mL
50 mM	0.0152 mL	0.0758 mL	0.1516 mL

Description

Tubeimoside I (Lobatoside H, TBMS1), a triterpenoid saponin, isolated from the tubers of Bolbostemma paniculatum, shows potent antitumor and antitumor-promoting effects.

In vitro

TBMS I inhibits the proliferation of both HepG2 and L-02 cells in a dose- and time-dependent manner, but HepG2 cells appear more sensitive to the agent. When exposed to TBMS I for 24, 48 and 72 h, IC50 for HepG2 cells versus L-02 cells are 15.5 vs. 23.1, 11.7 vs. 16.2, 9.2 vs. 13.1 (μM, p<0.01), respectively. TBMS I induces cell shrinkage, nuclear condensation and fragmentation, cell cycle arrest at the G2/M phase, mitochondrial membrane disruption, release of cytochrome c from the mitochondria, activation of caspase 3 and 9, and shifting Bax/Bcl-2 ratio from being anti-apoptotic to pro-apoptotic, all indicative of initiation and progression of apoptosis involving mitochondrial dysfunction.

In vivo

TBMS1 significantly inhibits the production of the pro-inflammatory cytokines, TNF-α, IL-6 and IL-1β in vitro and in vivo. Pretreatment with TBMS1 markedly attenuates the development of pulmonary edema, histological severities and inflammatory cells infiltration in mice with acute lung injury (ALI). TBMS1 exerts an anti-inflammatory effect in vivo model of ALI through suppression of IkB activation and p38/extracellular signal-regulated kinase mitogen-activated protein kinases signaling in a dose-dependent manner. TBMS1 could be a potent anti-tumor agent by inducing apoptosis in a variety of cancer types via the mitochondrial-related signaling pathway.

References

[1] Wang Y, et al. Biol Pharm Bull. 2011, 34(6):831-8.
[2] Wu Q, et al. Immunopharmacol Immunotoxicol. 2013, 35(4):514-23.

Synonyms

Olean-12-en-28-oic acid, 3-[[2-O-[4-O-[(3S)-4-carboxy-3-hydroxy-3-methyl-1-oxobutyl]-α-L-arabinopyranosyl]-β-D-glucopyranosyl]oxy]-2,23-dihydroxy-, 28-(O-β-D-xylopyranosyl-(1→3)-O-6-deoxy-α-L-mannopyranosyl-(1→2)-α-L-arabinopyranosyl) ester, intramol. 4′′(3)→4′′(28)-ester, (2β,3β,4α)-

Olean-12-en-28-oic acid, 3-[[2-O-[4-O-(4-carboxy-3-hydroxy-3-methyl-1-oxobutyl)-α-L-arabinopyranosyl]-β-D-glucopyranosyl]oxy]-2,23-dihydroxy-, 28-(O-β-D-xylopyranosyl-(1→3)-O-6-deoxy-α-L-mannopyranosyl-(1→2)-α-L-arabinopyranosyl) ester, intramol. ester, [2β,3β(S),4α]-

Lobatoside H

Tubeimoside I

Tubeimoside A

Tuberimoside 1

Tubeimoside 1